MYCobiome Analysis in Atopic Dermatitis With Head and Neck Involvement

Prior treatment

• Systemic or local antifungal therapy within 2 months before entry and during the study
• Systemic treatments for AD; including: ciclosporine, dupilumab and others AD biologics, methotrexate, JAK-inhibitors
• Psychiatric illness or any other concomitant chronic illness or addiction that could be interfere with the ability to meet the requirements of the protocol or provide informed consent

Other

• Current participation in another interventional research
• Patient with a measure of legal protection

• Age between 18 and 65 years;
• Male or female;
• The diagnosis of atopic dermatitis (AD) is defined according to the criteria of UK Working Party with at least 3 of the following 5 criteria are present; history of flexural involvement, history of a dry skin, onset under the age of 2, personal history of asthma or allergic rhinitis, history of a pruritic skin condition, and visible flexural dermatitis.
• Generalized AD defined by AD involved ≥50% of total body surface area with head and neck involvement. Or HNAD defined by AD involving at least 80% of the head and neck area with or without AD involvement outside the head and neck area but \<20% of total body surface area.
• With or without topical anti-inflammatory treatments for AD (including; topical steroids and/or topical tacrolimus)
• Free, informed and written consent, signed by the patient and the investigator before any examination required by the trial;
• Affiliation to social security scheme (beneficiary or assignee)
• Healthy control are the same age and sex.